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Hypertension affects 29% of US adults and is a significant risk
factor for cardiovascular morbidity and mortality.
Epidemiological data support contribution of several dietary
and other lifestyle-related factors to the development of high
blood pressure (BP). Several clinical trials investigated the
efficacy of non-pharmacological interventions and lifestyle
modifications to reduce BP. Best evidence from randomized
controlled trials supports BP-lowering effects of weight loss,
the Dietary Approaches to Stop Hypertension (DASH) diet,
and dietary sodium (Naþ ) reduction in those with
prehypertension, with more pronounced effects in those with
hypertension. In hypertensive participants, the effects on BP
of DASH combined with low Naþ alone or with the addition
of weight loss were greater than or equal to those of single-
drug therapy. Trials where food was provided to participants
were more successful in showing a BP-lowering effect.
However, clinical studies with long-term follow-up revealed
that lifestyle modifications were difficult to maintain.
Findings from controlled trials of increased potassium,
calcium, or magnesium intake, or reduction in alcohol intake
revealed modest BP-lowering effects and are less conclusive.
The reported effects of exercise independent of weight loss
on BP are inconsistent.
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Hypertension is a disease of epidemic proportions especially in
industrialized nations, affecting 29% of US adults alone.1 It was
identified as one of the most significant but modifiable risk
factors for not only cardiovascular (CV) disease, stroke, and
end-stage kidney disease2–6 but also for overall CV death.7,8
Despite this, the pathogenesis of primary hypertension is still
not completely understood. Epidemiological studies implicated
several dietary and other lifestyle-related factors contributing to
hypertension development. Extensive published evidence sup-
ports the concept that non-pharmacological interventions, more
recently referred to as lifestyle modifications, can substantially
reduce blood pressure (BP) in both individuals with established
hypertension and those with prehypertension. Evidence also
indicates that BP reduction decreases risk of poor CVoutcomes,
even in those with prehypertension.9
Large epidemiological studies such as International
Cooperative Study on the Relation of Sodium and Potassium
to Blood Pressure (INTERSALT) concluded that habitual
high sodium (Naþ ) intake, low potassium (Kþ ) intake,
decreased physical activity, high body mass index, and excess
alcohol intake may be critical environmental factors con-
tributing to rising prevalence of hypertension.10,11 INTER-
SALT, a large, cross-sectional epidemiological study done in
52 centers in 32 countries, confirmed that over a wide range
of Naþ intake, populations with low intake have lower BP
than those with high intake.10 Over the past few thousand
years, there was a major increase in Naþ content of the
human diet as a consequence of salt use in food preservation
and preparation. Parallel to this was a significant decrease in
dietary Kþ . The resultant dietary Kþ /Naþ ratio was reduced
by a factor of 100–200, based on the comparison of the
modern human diet with that of the Yanomamos, an
unacculturated tribe of Amazonian rain forest Indians.
Labeled as the ‘no-salt culture,’ they consume very little salt
as they live inland and are primarily gardeners and gatherers
with a largely vegetarian Kþ -rich diet.12 In observational
studies of Yanomamos, mean Naþ excretion was exception-
ally low at 0.9mmol/24 h, urinary Kþ was 152mmol/24 h,
and mean BP was 96/61mmHg.12 There was no increase in
BP with age and hypertension was virtually absent.11–14
Since then, there were several major clinical trials
exploring the efficacy of lifestyle modifications to reduce
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BP. In this article, evidence supporting the BP-lowering
effects of the following non-pharmacological interventions
will be reviewed: (1) the Dietary Approaches to Stop
Hypertension (DASH) diet; (2) reduced Naþ intake; (3)
increased Kþ intake; (4) increased magnesium intake; (5)
increased calcium intake; (6) weight loss and increased
physical activity; and (7) moderation in alcohol intake. Other
non-pharmacological interventions that were tried in smaller
clinical trials but revealed small and inconsistent effects will
not be reviewed. These include, but are not limited to,
increased protein intake, o-3 fatty acids, onion, garlic,
flavanol-rich cocoa, decreased caffeine intake, and device-
guided breathing and other biofeedback. Tobacco should be
avoided because of increased CV risk, regardless of evidence
for BP-lowering effects.
The DASH diet
The DASH Study tested the effects of an overall healthy diet,
rather than individual nutrients, on BP in participants with
prehypertension or stage I hypertension.15 This was based on
small effects observed on BP reduction in previous trials that
modified single nutrients (such as Kþ , magnesium, calcium,
fiber, and protein), as well as the generally positive results of
vegetarian diets.
A total of 459 adults with BP o160/80–95mmHg were
randomly assigned for 8 weeks to one of the following: (1)
control diet, low in fruits, vegetables, dairy products with a
fat content typical of the average US diet, and with Kþ ,
magnesium, and calcium levels close to the 25th percentile of
the US consumption; (2) fruits-and-vegetables diet, with Kþ
and magnesium at 75th percentile and with high fiber; or (3)
combination diet, rich in fruits, vegetables, and low-fat dairy,
with reduced saturated fat, total fat, and cholesterol, and Kþ ,
magnesium, and calcium at the 75th percentile.15 All the
three diets had similar Naþ content, 3 g/day. Weight was kept
stable.15
Percent of women and African-American participants, as
well as other characteristics of DASH and other major
lifestyle modification trials are tabulated in Table 1. Reduc-
tions in BP were achieved after 2 weeks in the fruits-and-
vegetables and combination diets as compared with the
control diet and were sustained for 6 more weeks. There
was a gradient reduction in both systolic and diastolic BP
across diets, with the combination diet reducing BP more
than the fruits-and-vegetables or the control diets (Table 2).
Those with hypertension (29%) and minorities (66%) had
greater reductions in BP, but there were no significant
interactions between minority status and diet or gender
and diet.15
In the Optimal Macronutrient Intake Trial to Prevent
Heart Disease (N¼ 164), two reduced carbohydrate versions
of DASH (high protein and high unsaturated fat) signifi-
cantly reduced BP by 3.5/2.4mmHg and 2.9/1.9mmHg,
respectively, in participants with hypertension when com-
pared with a higher carbohydrate DASH diet.16 A reduced
caloric version of DASH reduced BP by 16.1/9.9mmHg
when compared with control in the Exercise and Nutrition
Interventions for Cardiovascular Health Study (Table 1).17
Table 1 |Major trials of diet, weight, and sodium reduction for BP lowering
Trial Total, N Intervention(s) (vs control) Duration
Women
(%)
African-
American (%)
Overall BP reduction (mmHg)
compared with control
DASH 459 1. Fruits/vegetables diet
2. Combination/DASHa
8 weeks 49 60 2.8/1.1 Fruits/vegetables
5.5/3.0 Combination/DASH
OmniHeart 164 1. High protein (1/2 from plant sources)
2. High unsaturated fat
3. High carbohydrate
6 weeks 45 55 1.4/1.2 High protein vs carbohydrates
1.3/0.8 High unsaturated fat vs
carbohydrates
ENCORE 144 1. Usual diet
2. DASH alone
3. Reduced calorie DASH
4 months 67 39 3.4/3.8 Usual dietb
11.2/7.5 DASH alone
16.1/9.9 Reduced calorie DASH
DASH–Sodium 412 1. DASH—low Na+
2. DASH—intermediate Na+
3. DASH—high Na+
30 days 57 57 2.2/1.1 DASH—low Na+
5.0/2.5 DASH—intermediate Na+
5.9/2.9 DASH—high Na+
TOHP I 2182 Three lifestyle changes and four
nutritional supplements (see text)
18 months 30 15 2.3/2.9 Weight loss
2/1 Low Na+
TOHP II 2382 1. Weight loss
2. Low Na+
3. Combination of both
6 and 36
months
34 18 3.7/2.7 Weight lossc
2.9/1.6 Low Na+
4.0/2.8 Combined
DEW-IT 44 Combination of DASH, low Na+,
weight loss
9 weeks 62 62 9.5/5.3
(24 h ambulatory BP)
PREMIER 810 1. Establishedd
2. Established + DASH
6 months 62 34 3.7/1.7 Established
4.3/2.6 Established/DASH
Abbreviations: BP, blood pressure; DASH, Dietary Approaches to Stop Hypertension; DEW-IT, Diet, Exercise and Weight Loss Intervention Trial; ENCORE, Exercise and Nutrition
Interventions for Cardiovascular Health; OmniHeart, Optimal Macronutrient Intake Trial to Prevent Heart Disease; TOHP I, Trials of Hypertension Prevention—Phase I; TOHP II,
Trials of Hypertension Prevention—Phase II.
aCombination or DASH diet was rich in fruits, vegetables, and low-fat dairy, with reduced saturated fat, total fat, and cholesterol; potassium, magnesium, and calcium at levels
close to the US 75th percentile.
bReduction in BP in each group compared with preintervention values.
cRefers to BP reductions for 6 months.
dEstablished refers to a behavioral intervention that implemented established lifestyle recommendations.
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Dietary Naþ restriction
There are several clinical trials of dietary Naþ reduction, the
largest being the Trials of Hypertension Prevention—Phase I
(TOHP I) and the DASH–Sodium Trial (Table 1). The former
was a large multicenter, randomized trial in prehypertensives
of seven non-pharmacological interventions in the context of
usual living patterns. In Phase I, 6 of 10 sites tested an
intervention to reduce dietary Naþ intake to 80mmol/24 h
(1800mg/24 h), with a total of 417 control and 327 active
group participants.18 The intervention arm received nutrition
and behavior change counseling with the goal of reducing
Naþ intake to 60mmol/day (1400mg). The control arm
received no intervention.
At 18 months, net decrease from baseline in urinary Naþ
was 44mmol/24 h. White women had the highest proportion
of decreased urinary Naþ to target and African-Americans
had four times the odds of failing to achieve the target. Net
decrease in BP associated with treatment was 2/1mmHg
(Po0.01). There was a larger systolic BP effect in women
than men (4.4 versus 1.2mmHg, P¼ 0.02). Overall
adjusted decrease in BP was 1.4/0.9mmHg for a decrease of
100mmol/24 h in urinary Naþ .20 In an observational 10- to
15-year follow-up of TOHP, dietary salt reduction was shown
to significantly decrease long-term risk of CV events by 25%.9
In the DASH–Sodium Trial, 412 adults with BP 4120/80
and p159/95mmHg were randomly assigned to either a
control diet typical of the US intake or the DASH combination
diet.19 Within each group, participants were further assigned to
low Naþ (50mmol/day), intermediate (100mmol/day), or high
Naþ (150mmol/day) intake for 30 days in a random cross-over
design. Naþ intake reduction significantly lowered both systolic
and diastolic BP in a stepwise manner with both control and
DASH diets. Level of Naþ intake had about twice the effect on
BP with the control diet (6.7mmHg), as it did with the
DASH diet (3mmHg).19
Importantly, the DASH diet with low Naþ (as compared
with control diet/high Naþ ) led to a systolic BP 11.5mmHg
lower in hypertensives (which is greater than or equal to
the effects of single-drug therapy) and 7.1mmHg in
non-hypertensives.19 The combination of two dietary mod-
ifications (DASH and Naþ ) also lowered systolic BP
significantly more in women than in men.19 However, the
combined effects of DASH and low Naþ were not strictly
additive. The authors speculated that low levels of Naþ
attenuated the hypotensive effects of Kþ in DASH, or high
Kþ content attenuated the effects of low Naþ .
Weight loss
In TOHP I, seven interventions were tested in 2182
participants with prehypertension: three lifestyle changes—
weight reduction, Naþ reduction, and stress management—
compared with unmasked non-intervention controls, and
four nutritional supplements—Kþ (60mmol or 4.5 g),
calcium (25mmol or 1 g), magnesium (15mmol or
360mg), and fish oil (6 g with 3 g of o-3 fatty acids)—
compared singly with placebo in a double-blind manner.
Follow-up for the lifestyle changes interventions was 18
months to test maintenance of behavioral changes. Interven-
tion included counseling on food selection, and the weight
reduction group incorporated a moderate increase in caloric
expenditure by walking briskly for 45min 4–5 times weekly.20
Weight reduction was the most effective strategy, pro-
ducing a net weight loss of 3.9 kg and a BP change of 2.3/
2.9mmHg (Po0.01). Effect of Naþ reduction on BP
was discussed above. Stress management and nutritional
supplements did not reduce BP significantly despite good
adherence.20
Achieved weight loss was greater in men than in women.
The effect on BP was linearly associated with the amount
of weight lost. After 7 years of follow-up, the odds of
hypertension were reduced by 77% (P¼ 0.02) in the weight
loss group compared with controls. These data suggest that
weight loss may be effective in long-term primary prevention
of hypertension.21
Combination of weight loss and Naþ reduction
The Phase II of TOHP was 2 2 factorial trial that
randomized 2382 participants to one of four groups: weight
Table 2 |Mean reductions in BP from baseline in the DASH Triala15
Group
Combination minus
control (97.5% CI), P-value
Combination minus fruits/vegetables
(97.5% CI), P-value
Fruits/vegetables minus control
(97.5% CI), P-value
Systolic BP (mmHg)
All 5.5 (7.4, 3.7) o0.001 2.7 (4.6, 0.9) 0.001 2.8 (4.7, 0.9) o0.001
o140/90 3.5 (5.3, 1.6) o0.001 2.7 (4.5, 0.8) 0.001 0.8 (2.7, 1.1) NS
X140/90 11.4 (15.9, 6.9) o0.001 4.1 (8.6, 0.3) NS 7.2 (11.4, 3.0) o0.001
Minority 6.8 (9.2, 4.4) o0.001 3.2 (5.6, 0.8) 0.003 3.6 (6.1, 1.2) 0.001
Non-minority 3.0 (5.9, 0.1) 0.02 1.9 (4.8, 1.0) NS 1.1 (3.9, 1.7) NS
Diastolic BP (mmHg)
All 3.0 (4.3, 1.6) o0.001 1.9 (3.3, 0.6) 0.002 1.1 (2.4, 0.3) NS
o140/90 2.1 (3.6, 0.5) 0.003 1.8 (3.4, 0.3) 0.009 0.3 (1.9, 1.3) NS
X140/90 5.5 (8.2, 2.7) o0.001 2.6 (5.4, 0.1) NS 2.8 (5.4, 0.3) 0.01
Minority 3.5 (5.2, 1.8) o0.001 2.1 (3.8, 0.4) 0.007 1.4 (3.2, 0.3) NS
Non-minority 2.0 (4.2, 0.2) 0.04 1.6 (3.8, 0.5) NS 0.4 (2.5, 1.7) NS
Abbreviations: BP, blood pressure; CI, confidence interval; DASH, Dietary Approaches to Stop Hypertension; NS, not significant.
aAdapted from Appel et al.15
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loss alone, Naþ reduction alone, combination of both, or
usual care.22 Intervention counseling aimed at achievement
of desirable weight or a X4.5-kg weight loss and/or Naþ
intake of 80mmol/day.
Compared with usual care, the weight loss and combined
groups had similar weight reduction (4.1–4.4 kg) at 6 months
(Po0.001 for both).22 Weight reduction in the Naþ alone group
was 1.1 kg, 1.2 kg less than usual care (Po0.001). However, by
36 months, weight regain occurred in all groups, resulting in a
weight close to baseline in the weight loss and combined groups.
Similarly, the main effect of the Naþ intervention fell short of
goal, and the net reduction was 48mmol/day.22
BP reductions at 6 months for each group versus usual
care are listed in Table 1 (Po0.001 for all comparisons).22
However, at 36 months, these reductions were attenuated and
remained statistically significant only for diastolic and
systolic BP in the weight loss group and for systolic BP in
the Naþ group. This trial revealed that long-term interven-
tions for weight loss and dietary Naþ reduction are difficult
to maintain. In addition, long-term maintenance of weight
loss was less successful than Naþ reduction.
A three-pronged approach—DASH diet, reduced Naþ,
and weight loss—was investigated in the Diet, Exercise and
Weight Loss Intervention Trial (DEW-IT), where 44
hypertensive overweight adults with a BP of 130–170/
80–100mmHg on stable dose of a single antihypertensive
medication or combination pill were randomized to a
lifestyle or control group for 9 weeks.23 The lifestyle group
was fed a hypocaloric version of DASH providing 100mmol/
day of Naþ and participated in a moderate-intensity aerobic
exercise of 30–45min three times a week. All foods were
provided to the participants. There were no interventions in
the control group.23
Mean net weight loss in the lifestyle group was 4.9 kg, and
net mean reduction in 24-h ambulatory BP (the primary
outcome) was 9.5/5.3mmHg (Po0.001). The main conclu-
sions were: (1) BP reduction in DEW-IT was similar to that
achieved in the DASH–Sodium Trial in the hypertensive
subgroup, not on antihypertensive medication and (2) the BP
reduction magnitude was similar to BP reductions achieved
with drug therapy.23
The PREMIER clinical trial of comprehensive lifestyle
modification for blood pressure control randomized 810 adults
with prehypertension or stage I hypertension not on drug
therapy to: (1) established, a behavioral intervention that
implemented the established JNC (Joint National Committee on
Prevention, Detection and Evaluation of High Blood Pressure)
VI recommendations; (2) established plus DASH, which added
the DASH diet; or (3) advice-only comparison group, which
received advice at randomization. Interventions included: (1)
weight loss of at least 15 lb (6.8 kg) if body mass indexX25 kg/
m2; (2) moderate-intensity exercise of X180min/week; (3)
p100mmol/day of Naþ intake; (4)p2 alcohol drinks/day for
men and p1 for women; and (4) 18 counseling sessions.24
Mean net BP reduction at 6 months compared with the
advice-only group was 3.7/1.7mmHg in established, and
4.3/2.6mmHg in established plus DASH. The addition of
DASH only provided an incremental 1.7/1.6mmHg BP
reduction. Corresponding BP reductions for hypertensive
participants were higher at 4.6/2.0 and 6.3/3.6mmHg,
respectively.24
Why were BP reductions achieved in PREMIER smaller than
achieved in previous trials? In DEW-IT and DASH, food was
provided to the participants but in PREMIER, participants
purchased their own food; hence, the same intensity of
intervention may not have been achieved. In addition, 62% of
DEW-IT and 57% of DASH but only 34% of PREMIER
participants were African-Americans.25 Therefore, salt sensitivity,
more prevalent in African-Americans, may have had a role.
Finally, the duration of intervention in PREMIER was 6 months,
whereas it was shorter in the other trials: 30 days in DASH and 9
weeks in DEW-IT.25 Similarly, the BP reductions in TOHP I were
small at 18 months.20 This may be due to difficulty in
maintaining lifestyle changes over a prolonged period.
Increased Kþ intake
INTERSALT showed a negative association between 24-h Kþ
excretion and systolic BP, which after adjustment for age,
gender, body mass index, alcohol consumption, and Naþ
excretion was statistically significant in only 3 of 52 centers.10
However, less than 10% of participants were Black and
stratification by race was not undertaken.10 Previous studies
demonstrated that Kþ intake may have an important role in
salt-sensitive hypertension particularly in Blacks.26,27 Salt
loading increased mean arterial BP by 6.8mmHg in Black
versus 1.9mmHg in White participants given a low Kþ diet.
This effect was attenuated when Kþ intake was increased.27
This and other studies implicated the importance of well-
representing African-Americans in trials of Kþ -intake
manipulation, especially as this racial group not only is at
higher risk for hypertension and its clinical consequences28–32
but also has lower dietary Kþ intake than Whites, as reported
in NHANES III.29
One potential mechanism explaining these racial differ-
ences could be overexpression of long WNK1 (with no lysine
kinase 1). A deletion in the first intron of the WNK1 gene
increases expression of the long isoform and causes familial
hyperkalemic hypertension, featured by hypertension and
hyperkalemia.33–35 Long WNK1 stimulates Naþ reabsorption
via the epithelial Naþ channel, leads to activation of the
thiazide-sensitive Naþ–Cl cotransporter by inhibiting
WNK4,36–38 and inhibits Kþ secretion via the apical Kþ
channel (ROMK).33 Kidney-specific WNK1, a truncated
form expressed only in kidney, antagonizes both long
WNK1 effects, and, therefore, may decrease Naþ retention
and increase Kþ excretion. Dietary Kþ restriction in rats
increased whole-kidney long WNK1 mRNA levels while
decreasing that of kidney-specific WNK1, and a high Kþ diet
resulted in the opposite.39 Lower dietary Kþ intake in
African-Americans may increase the ratio of long WNK1:
kidney-specific WNK1 in kidney, resulting in reduced renal
Kþ secretion to conserve Kþ , at the expense of increasing
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renal Naþ reabsorption and leading to salt retention and
hypertension (Figure 1).33
Clinical trials reported conflicting data about beneficial
effects of increased Kþ intake on BP,26,40–69 and evidence
generally supports a positive effect in the short-term that is
not sustained long-term. Heterogeneity of results may also be
because of low representation of African-Americans and
decreased efficacy of Kþ intake in lowering BP when
accompanied by low Naþ intake.69 In a meta-analysis of 33
randomized controlled trials (N¼ 2609), Kþ supplementa-
tion was associated with a significant BP reduction of 3.1/
2.0mmHg.70 Treatment effects appear to be enhanced in
trials where participants were concurrently exposed to a high
Naþ intake or were hypertensive.70,71 Kþ supplementation
caused a modest 1.18mmHg reduction in diastolic BP at 3
months in the TOHP I Trial that was not significant at 6
months.68 Finally, 96mmol of KCl versus placebo did not
reduce the need for antihypertensive medications in a 2-year
trial of 287 hypertensive and predominantly White males.69
Although long-term data to confirm the efficacy of Kþ
supplementation for BP lowering is not conclusive, it is
possible that the effect of Kþ intake on BP is small and not
detected easily by clinical trials, but becomes clinically
relevant from a population-based perspective, as observed
in epidemiological studies such as INTERSALT.69
Data are conflicting regarding the effects of KCl versus Kþ
alkali (bicarbonate or citrate) and vary from showing no
effect on BP of either KCl or Kþ alkali,72,73 equivalent BP-
lowering effects,74–77 to Kþ alkali having a substantially
stronger effect than KCl.78 It is difficult to draw conclusions
from these studies, given the possible confounding from
variability of dosage and treatment durations, racial differ-
ences, and other dietary factors, such as Naþ and
magnesium.
Increased magnesium intake
Epidemiological studies show an inverse relationship between
dietary magnesium intake and hypertension prevalence
despite limitations such as use of dietary questionnaires as
measures of intake. In the Nurses’ Health Study, the relative
risk of hypertension for a magnesium intake 4300mg/day
compared with an intake o200mg/day was 0.78.79 The
Honolulu Heart Study reported that of 61 nutritional
substances studied, magnesium intake had the strongest
inverse association with BP.80
Despite compelling epidemiological data, results of clinical
trials are conflicting. Some studies show significant reduc-
tions in BP,81–83 whereas others do not.84–86 A recent trial in
hypertensives reported a statistically significant decline in
office, home, and ambulatory BP after 8 weeks of 480mg
magnesium/day in the form of magnesium oxide.87 Lind
et al.86did not detect an effect of magnesium supplementa-
tion overall, but BP was lowered in a subgroup of
patients with magnesium deficiency (low urinary magnesium
K+
Na+
Na+
Na+
CI–
ENaC
+
+
–
NCC
ROMK
K+
excretion
Blood
pressure
Restoration
of K+ status K+ deficiency
Low K+ intake
L-WNK1
KS-WNK1
K+ K+
Figure 1 | Illustration of a model of sodium (Naþ ) retention causing hypertension in a state of dietary potassium (Kþ ) deficiency,
mediated by WNK1. During Kþ depletion, to maintain Kþ levels, ROMK is downregulated (by endocytosis of ROMK). This downregulation
is mediated by an increase in the ratio of L-WNK1 to KS-WNK1 in the kidney, which decreases renal Kþ secretion to conserve Kþ , but
also enhances renal Naþ reabsorption via ENaC and NCC, resulting in Naþ retention and hypertension. Adapted from Huang et al.33
Cl, chloride; ENaC, epithelial sodium channel; Naþ , sodium; NCC, Naþ/Cl cotransporter; ROMK, renal outer medullary potassium channel;
WNK1, with no lysine kinase 1; KS-WNK1, kidney-specific WNK1; L-WNK1, long WNK1.
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excretion). Dyckner and Wester81 reported that magnesium
supplementation reduced BP by 12/8mmHg in patients on
long-term diuretics, a subgroup of patients more likely to be
magnesium depleted.
The discrepancies may be the result of small sample sizes,
differing preparations and concentrations of magnesium, and
heterogeneity of samples. Trials that showed no effect used
smaller doses of magnesium, 10–15mmol/day compared with
X20mmol/day in studies that demonstrated BP lowering.88
Subgroups that demonstrated BP lowering included African-
Americans and those on diuretics.
Increased calcium intake
Analysis of the Korean National Health and Nutrition
Examination Survey III showed that calcium supplementa-
tion was inversely associated with diastolic BP.89 In a meta-
analysis, Mierlo et al.90,91 reported BP-lowering effect of
calcium supplementation, although some studies had nega-
tive results. A Cochrane systematic review of 13 trials that
included415,000 women reported calcium supplementation
decreased risk of developing hypertension during pregnancy
by 35%.92 However, a large double-blind placebo-controlled
trial of 6 months duration, TOHP I, failed to show a BP-
lowering effect with 1g/day of calcium supplementation.20
Effects of exercise independent of weight loss
There is data suggesting exercise can lower BP independently
of weight loss. Many of studies used conventional BP
measurements, but studies using ambulatory-BP monitoring
have more conflicting results. Interestingly, people who
adhere to home-BP monitoring are more compliant with
exercise programs.93 It is believed that sedentary individuals
experience an exaggerated increase in BP during physical
activity, and some data suggest that aerobic exercise
normalizes such an exaggerated response and lowers BP in
these individuals.94
In a meta-analysis of 54 randomized controlled trials
(N¼ 2419) whose intervention and control groups differed
only in aerobic exercise, aerobic exercise was associated with
a statistically significant reduction in BP of 3.8/2.6mmHg.95
The reduction in BP was similar in normotensive versus
hypertensive participants. Importantly, mean BP reduction
was not associated with changes in body weight, and BP was
reduced in participants that did not lose weight.
Another meta-analysis of 11 exercise trials (N¼ 320) of
both normotensives and hypertensives that included a
randomized non-exercise control group, progressive resis-
tance exercise as the only intervention, and duration of
at least 4 weeks reported a BP reduction of 3±3/
3±2mmHg.96–107 In a recent study of 118 prehypertensives,
those with endothelial nitric oxide synthase gene polymorph-
ism had about 20% increase in NO and 10% decrease in BP
in response to aerobic exercise.108
In contrast to the above data, the effect of exercise on
ambulatory-BP monitoring is not consistent. Some studies
showed that low-intensity aerobic exercise for 6–12 months
reduced BP (mostly diastolic) by about 5mmHg,109–111
whereas other studies did not.112 In a review of 23 studies
that examined the effect of dynamic exercise on ambulatory-
BP monitoring, there was an average decrease in 24-h systolic
BP by 3.2 and diastolic BP by 1.8mmHg.113
Moderation in alcohol intake
Consumption of alcohol was associated with increased BP in
observational studies.10,114,115 Abramson et al.114 showed that
binge drinking and habitual alcohol consumption are
associated with higher mean ambulatory BP in normotensive
adults.114 Similarly, a Japanese study of 539 participants
showed that alcohol intake was independently associated
with an increase in morning BP.115
Clinical trials investigating the effects of alcohol reduction
on BP were limited by small samples, short duration, and
inconsistent findings.116–130 A meta-analysis of 15 rando-
mized controlled trials (N¼ 2234) in which alcohol reduc-
tion was the only intervention reported a significant decrease
in BP of 3.3/2.0mmHg and a dose-response relationship
between alcohol reduction and BP.131 Median length of trials
was 8 weeks. Seven trials included behavioral interventions,
and 8 used low-alcohol beer substitute. Effects were more
pronounced in those with higher baseline BP.
On the other hand, the Prevention and Treatment of
Hypertension Study that randomized 641 male veterans to a
cognitive-behavioral alcohol reduction intervention or a
control group failed to show a statistically significant
difference at 6 months.130 Lack of efficacy in this trial could
include lower alcohol reduction intervention effect and
longer duration of observation. In addition, a net weight
reduction seen in some of the other alcohol intervention
trials could have confounded the BP reduction observed.
CONCLUSIONS
There is sufficient data to suggest that certain lifestyle
modifications, such as weight loss and Naþ intake reduction,
are efficacious in lowering BP, reducing progression of
prehypertension to hypertension, and perhaps diminishing
long-term risk of CV events2,9,132,133 (Table 3). However, the
effectiveness of such lifestyle modifications needs to be
further established in population-based studies, as imple-
mentation of healthier lifestyles is challenging. For example,
in both the DASH and the TOHP trials, the greatest BP-
lowering effect was seen when Naþ intake was reduced to
very low levels (33–50mmol/day), a goal that is difficult to
achieve.132 One barrier is the affordability of a diet rich in
fruits-and-vegetables and low in Naþ , especially for racial
groups where such dietary modifications ironically had the
greatest impact on BP. In addition, reduction of discretionary
salt may contribute little to moderation of total Naþ intake,
as in one study 77% of total Naþ intake was derived from
processing added salt, and cooking and table salt contributed
only 11.3%.134 Additional motivation would be needed in
those with prehypertension who do not have to face the
alternative of taking medications.20 Long-term lifestyle
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interventions are difficult to maintain, and simultaneous
interventions using two or more lifestyle changes, such as
weight loss and Naþ reduction, may have little effect over
and above interventions designed to modify one aspect.
However, modification of combination of dietary nutrients,
such as DASH versus single nutrients met with greater
success. The future challenge is developing and implementing
effective public health strategies that lead to sustained lifestyle
modification.132 New strategies could include an excise tax on
the food industry to decrease Naþ content. Such a tax to
decrease Naþ intake by 6% could save $22.4 billion in
medical costs.135
Naþ retention is a major player in hypertension in
chronic kidney disease patients,136 although such patients are
generally excluded from trials of non-pharmacological
interventions. The DASH diet has higher Kþ , phosphorus,
and protein content than what is generally recommended for
patients with moderate-to-advanced chronic kidney disease
and may not be ideal. Studies suggested that low-protein
diets may slow chronic kidney disease progression.137
Randomized trials of chronic kidney disease samples are
needed to determine ideal diet and lifestyle modifications for
BP lowering in this population.
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